EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...

Cystoid macular edema (CME) is a condition characterized ... The review highlighted various causes, including drug-induced cases, and emphasized the need for further investigation into treatment ...

In October, Oxular began a phase 2 trial for its therapeutic candidate OXU-001, for treatment of diabetic macular edema ...

Diabetic macular edema remains an important cause of vision loss among patients with diabetes mellitus. Improved control of blood pressure and blood sugar, as well as photocoagulation, are ...

With DME being a leading cause of vision loss in diabetics and ... wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Their lead product candidate, sozinibercept, is ...

Mississauga, Ontario Tuesday, January 21, 2025, 14:00 Hrs [IST] ...

Kodiak Sciences Inc. , a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today ...

The phase 3 trial showed biosimilar CT-P42 (Celltrion) is therapeutically equivalent to reference aflibercept in improving visual acuity in patients with diabetic macular edema (DME), with comparable ...

macular edema caused by a blockage in the retinal vein diabetic retinopathy diabetic macular edema Eylea is also used to treat retinopathy of prematurity, an eye condition that can affect ...